Leukemia inhibitory factor receptor inhibition reduces stenosis grade and total serum cholesterol levels in a mouse model for atherosclerosis

E Hemme,M A C Depuydt,P J Van Santbrink,L Delfos,J Kuiper,I Bot
DOI: https://doi.org/10.1093/cvr/cvae088.206
IF: 13.081
2024-05-31
Cardiovascular Research
Abstract:Funding Acknowledgements Type of funding sources: Foundation. Main funding source(s): Dutch Heart Foundation Atherosclerosis is characterized by the accumulation of lipids and immune cells in the arterial wall and it is the main underlying pathology causing cardiovascular diseases (CVD). Cytokines are involved in all stages of atherosclerosis and most cytokines contribute to disease progression. For instance, IL-6 cytokine family members, such as IL-6, oncostatin-M and cardiotrophin-1, are closely related to CVDs. However, the role of leukemia inhibitory factor (LIF), a member of the IL-6 cytokine family, and its receptor (LIFR) in atherosclerosis remains unknown. Therefore, the aim of this study is to assess the contribution of LIFR signaling to atherosclerosis development by systemically inhibiting LIFR in an atherosclerotic mouse model. First, the expression of LIF and LIFR was examined using single-cell RNA sequencing data of human carotid artery plaques. Mast cells highly and exclusively express LIF, whereas LIFR was specifically expressed by activated endothelial cells. To validate LIFR signaling in vivo, female western-type diet fed Ldlr-/- mice were treated with LIFR inhibitor EC359 (5 mg/kg s.c., n=15) or control solvent (n=15) three times per week for eight weeks. During the experiment, weights of the mice did not differ between groups, whereas total serum cholesterol levels were significantly reduced in EC359 treated mice (p=0.03). In particular, EC359 treatment reduced VLDL levels. Additionally, EC359 treatment significantly reduced Sr1, Abca1 and Lrp1 expression in the liver, suggesting an altered lipid metabolism in EC359 treated mice. Furthermore, LIFR inhibition affected innate immunity, both systemically and locally in the plaque. Neutrophil numbers were significantly increased in the circulation (ctrl 18.7±1.7%; EC359 28.0±2.0%; p=0.002) and aortic plaques (ctrl 3.9±0.8%; EC359 9.9±1.9%; p=0.003) of mice treated with EC359 compared to control mice. Moreover, LIFR inhibition affected circulating monocytes resulting in less inflammatory monocytes. The adaptive immune cells, such as T and B cells, remained largely unaffected. Collectively, the reduction of serum total cholesterol and increase in neutrophil numbers in EC359 treated mice resulted in a trend towards reduced atherosclerotic stenosis grade compared to control mice (39.8±1.4% versus 34.9±1.9%; p=0.054), but it did not affect plaque collagen and monocyte/macrophage content in the aortic root. Conclusively, LIFR signaling inhibition reduces atherosclerotic stenosis grade, lowers plasma total cholesterol levels and affects innate immunity.
cardiac & cardiovascular systems
What problem does this paper attempt to address?
This paper aims to explore the role of leukemia inhibitory factor receptor (LIFR) in the development of atherosclerosis and evaluate the impact of systemic inhibition of LIFR on atherosclerosis. Specifically, the researchers hope to use the LIFR inhibitor (EC359) to observe whether it can reduce the degree of arterial stenosis and lower the total serum cholesterol level in a mouse model, thereby providing new targets and strategies for the treatment of cardiovascular diseases. ### Research Background Atherosclerosis is a disease characterized by the accumulation of lipids and immune cells in the arterial wall, and it is the main pathological basis for cardiovascular diseases (CVD). Cytokines play important roles in all stages of atherosclerosis, and most cytokines promote the progression of the disease. For example, members of the IL - 6 cytokine family such as IL - 6, oncostatin - M, and cardiotrophin - 1 are closely related to cardiovascular diseases. However, the role of leukemia inhibitory factor (LIF) and its receptor (LIFR), which are members of the IL - 6 cytokine family, in atherosclerosis has not been clearly defined. ### Research Methods 1. **Single - cell RNA sequencing**: The researchers first used single - cell RNA sequencing data to detect the expression of LIF and LIFR in human carotid plaques and found that mast cells highly expressed LIF, while activated endothelial cells specifically expressed LIFR. 2. **Animal experiments**: Subsequently, the researchers conducted a treatment experiment with the LIFR inhibitor EC359 in a Western - diet - fed Ldlr - / - mouse model. The mice in the experimental group were subcutaneously injected with 5 mg/kg of EC359 three times a week, and the control group was injected with an equal amount of solvent for 8 weeks. ### Main Results - **Serum cholesterol level**: EC359 treatment significantly reduced the total serum cholesterol level in mice (p = 0.03), especially the VLDL level. - **Liver gene expression**: EC359 treatment significantly reduced the expression of Sr1, Abca1, and Lrp1 in the liver, suggesting that lipid metabolism has been altered. - **Immune response**: LIFR inhibition affected the innate immune response, as manifested by a significant increase in the number of neutrophils in the circulation and aortic plaques (in the circulation: ctrl 18.7 ± 1.7%, EC359 28.0 ± 2.0%, p = 0.002; in the plaques: ctrl 3.9 ± 0.8%, EC359 9.9 ± 1.9%, p = 0.003). In addition, EC359 treatment also reduced inflammatory monocytes in the circulation, but had little effect on adaptive immune cells (such as T cells and B cells). - **Arterial stenosis degree**: Although there was a downward trend in the degree of arterial stenosis in mice after LIFR inhibitor treatment (39.8 ± 1.4% vs 34.9 ± 1.9%, p = 0.054), it did not reach statistical significance. At the same time, the treatment did not affect the collagen and monocyte/macrophage content in the plaques. ### Conclusion In summary, inhibition of the LIFR signaling pathway can reduce the degree of atherosclerotic stenosis, lower the total plasma cholesterol level, and affect the innate immune response. These findings provide potential targets and strategies for the development of new treatments for cardiovascular diseases.